SAN DIEGO , Nov. 5, 2024 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today that Zev Wainberg , MD, an internationally renowned medical oncologist and professor at David Geffen School of Medicine at UCLA , has joined the Company's Clinical Advisory Board (CAB).
"We are excited to have Professor Wainberg joining our Clinical Advisory Board," said Ming Wang , PhD, MBA, Phanes' Chief Executive Officer. "Dr. Wainberg is a leading medical oncologist in gastrointestinal malignancies.
He will join the other leading experts on our CAB to provide valuable guidance and advice on the three clinical programs at Phanes. His extensive expertise and experience will enhance Phanes' strength in drug development and ability to deliver innovative therapies for cancer patients." Biograph of Professor Zev Wainberg Zev Wainberg , MD Dr.
Wainberg is an academic medical oncologist at the David Geffen UCLA School of Medicine specializing in gastrointestinal malignancies. He currently serves as the co-director of the GI oncology program and medical director of the Pancreas Cancer Center at UCLA with a joint appointment in medicine and surgery. His research focus is on translational research of GI cancers with a particular focus on drug development.
He also serves as the director of the Early Phase Clinical Research Program at the Jonsson Comprehensive Cancer Center at UCLA . He is curren.
